To examine whether the hypothalamic corticotropin-releasing hormone (CRH) neuron is regulated by CRH, by products of the proopiomelanocortin (POMC) gene, and/or by glucocorticoids, we used a rat hypothalamic organ culture system in which rat CRH secretion from single explanted hypothalami was evaluated by an RIA (iCRH) specific for rat CRH. The effects of graded concentrations of ovine CRH (oCRH), adrenocorticotropin hormone (ACTH), 6-endorphin (f-EP), a-melanocyte-stimulating hormone (a-MSH), corticotropin-like intermediate lobe peptide (CLIP), ovine ft-lipotropin (ovine f-LPH), and dexamethasone (DEX) upon unstimulated and serotonin-(5HT), acetylcholine-(ACh), and norepinephrine-(NE) stimulated CRH secretion were determined. oCRH and DEX inhibited unstimulated iCRH secretion with ID50 at the 10-8 M range. ACTH had no detectable suppressive effect at 10-8 M. oCRH, ACTH, and DEX inhibited 5HT-, ACh-, and NE-stimulated iCRH secretion in a dose-dependent fashion.
Introduction
The activity of the hypothalamic-pituitary-adrenal (HPA)' axis is regulated by circadian and stress-related excitatory inputs, inhibitory neural modulation, and various negative feedback control loops. Ultrashort-loop feedback of hypothalamic releasing/inhibiting hormones on their own secretion was postulated by Martini and co-workers (1) . Recently, such autoregulatory mechanisms were demonstrated for oxytocin, growth hormone-releasing hormone, somatostatin, and luteinizing hormone-releasing hormone (2-5). Moreover, Ono and co-workers proposed that although corticotropin-releasing hormone (CRH) exerts no ultrashort-loop negative feedback under basal conditions, it may stimulate rather than inhibit its own secretion in stress states (6) . Direct evidence for a positive or a negative ultrashort CRH feedback loop would be necessary to clarify this issue.
Observations from animal studies have suggested that circulating ACTH may restrain its own secretion (7, 8) . Whether this postulated ACTH autoregulation takes place directly at the pituitary level as an ultrashort negative feedback loop or is mediated via inhibition of CRH secretion from the hypothalamus, participating thus as a short negative feedback loop, remains uncertain. A direct pituitary self inhibition of ACTH has been suggested by in vitro studies using mouse pituitary tumor cells producing ACTH (9) , and in a recent clinical study (10) . This type ofcontrol, however, could not be demonstrated in dispersed rat anterior pituicyte cultures (1 1). The presence, on the other hand, of a short-loop negative feedback effect of ACTH on hypothalamic CRH secretion has been recently suggested ( 12, 13) .
Long-loop negative feedback is exerted by glucocorticoids at the pituitary corticotroph cell, the hypothalamic CRH-secreting neuron and possibly at sites of the limbic system, like the amygdala and the hippocampus. A pituitary and a hypothalamic locus for glucocorticoid inhibition of HPA axis function have been demonstrated clearly in both in vivo and in vitro experiments .
This study was undertaken to determine whether or not basal and stimulated CRH secretion from isolated rat hypothalami is affected by CRH,. products of the proopiomelanocortin (POMC) gene such as ACTH, f3-endorphin (f3-EP), amelanocyte-stimulating hormone (a-MSH), corticotropin-like intermediate lobe peptide (CLIP) , and ovine fl-lipotropin (ovine f3-LPH), or glucocorticoids. To accomplish this task, we examined the effects of each of these factors upon hypothalamic CRH secretion in vitro. The study was conducted using 3 (±SE) and 1.9±0;1% for TS-3A and 36±4 and 2.1±0.1% for TS-3B, respectively. Sensitivity (ED90) was 2.0±0.1 pg/tube (20 pg/ml of media) for the assays using TS-3A and 2.8±0.2 pg/tube (28 pg/ml of media) for the assays using TS-3B. The intraassay and the interassay coefficients of variation were 8.1 and 17.2%, respectively, for TS-3A antiserum and 7.2 and 15.1%, respectively for TS-3B antiserum.
TS-3A and TS-3B antisera showed no significant cross-reactivity (42) .
Results
Mean (±SE) unstimulated iCRH secretion was 36±2 pg/0.4 ml/hypothalamus per 20 min (n = 32). iCRH secretion in plain medium was constant for 180-200 min of incubation, whereas there was a gradual increase thereafter. Accordingly, the total iCRH AUC121-240 was about threefold greater than AUCI-120. The effects of different concentrations of oCRH, ACTH, and DEX upon the unstimulated iCRH secretion are shown in Fig. 1 CLIP, and ovine ,B-LPH on 5HT-induced iCRH secretion are shown in Fig. 3 . ,B-EP inhibited 5HT-stimulated iCRH secretion from 10-10 to 10-7 M (P < 0.05 vs. 5HT alone, DUN; A). (46) (47) (48) (49) (50) (51) . Using our system, we have shown that 5HT, ACh, and NE stimulate iCRH secretion in a dose-dependent fashion with peak effect at 10-9 M. These effects can be antagonized by the respective antagonists and appear to be direct rather than mediated by interneurons (39, 43, 44) . The stimulatory nature of 5HT and ACh has been suggested by older and recent in vivo and in vitro studies (46) (47) (48) . According to our data, NE is a potent stimulatory neurotransmitter for the central component of the HPA axis (44) , rather than inhibitory as previously suggested (51) . This finding supports an increasing body of literature according to which the ascending noradrenergic projection to the PVN stimulates CRH secretion (49, 50) .
Exogenous CRH was able to inhibit both unstimulated and neurotransmitter-stimulated iCRH secretion in vitro, a result compatible with the presence of an ultrashort negative feedback loop. 5HT-and NE-induced iCRH secretion were very sensitive to the suppressive effects of the ovine analogue of CRH, whereas suppression of basal and ACh-induced iCRH secretion required concentrations of oCRH that were four orders of magnitude higher. The concentrations of oCRH required to inhibit both unstimulated and neurotransmitterstimulated iCRH secretion in vitro were of the same order of magnitude as those reported in the hypophysial portal blood system of stressed rats (27). Neither the source nor the site of action ofendogenous CRH involved in an ultrashort-loop negative feedback are known with certainty. The median eminence that contains CRH in nerve terminals may be both a source of endogenous CRH and a target for the inhibitory effects of CRH. Compatible with the latter hypothesis is autoradiographic evidence for the presence ofCRH receptors in the external zone of the median eminence (52). Alternatively and/or additionally, CRH may suppress hypothalamic CRH neuron activity by acting at the PVN level. There is electrophysiological evidence for the presence of recurrent CRH inhibitory collaterals to the PVN itself (53) . Our data do not provide any evidence for the existence of a positive feedback loop of CRH on its own secretion as previously suggested (6) , indicating that the in vivo effect observed by these investigators may be due to additional unknown mechanisms.
ACTH, fl-EP, a-MSH, and CLIP inhibited neurotransmitter-stimulated iCRH secretion, a result compatible with the presence of a short POMC peptide-mediated negative feedback loop. Previous reported observations have indicated that both ACTH and S-EP inhibit hypothalamic CRH secretion. ACTH implanted in the median eminence of rat suppressed blood corticosterone levels (7) . ACTH also was shown to inhibit unstimulated iCRH secretion in a dose-dependent fashion in vitro. This inhibitory effect was partially retained (-60%) by a-MSH, but not by CLIP (12) . Sl-EP has been shown to suppress ACTH and cortisol levels in normal subject (54) and to inhibit both corticotropin-releasing bioactivity (CRB) and iCRH secretion in vitro (55, 56 Our results suggesting the presence of a long glucocorticoid-mediated negative feedback loop are consistent with studies conducted with similar or different experimental paradigms. In this regard, it has been shown that CRB content of the hypothalamus and the sensitivity of CRB secretion to various stimuli are increased after adrenalectomy and both effects are reversed by glucocorticoid administration (29, 30, 33, 34) . Furthermore, stress-induced and basal CRB content of the hypothalamus and the median eminence are suppressed by glucocorticoid administration (24) (25) (26) or by DEX implants in the median eminence (66). DEX treatment is also able to prevent the increase of CRH immunoreactivity in the hypophysial portal blood of rats undergoing hemorrhage-induced stress (27) . Adrenalectomy has been shown capable to increase hypothalamic levels of prepro-CRH mRNA, although a more marked effect has been observed on pituitary POMC mRNA (31) . Recently, a number of immunohistochemical studies have been done to clarify the brain site(s) of glucocorticoid action (67, 68) . It seems that the PVN and the hippocampus could be the major targets for the glucocorticoid negative feedback. Local implantation of DEX in these regions, but not in the amygdala or cerebral cortex, can prevent the expected adrenalectomy-induced enhancement of CRH and vasopressin immunoreactivity in the PVN (67, 68 ). This conclusion is strengthened by data showing the presence of glucocorticoid receptors in the PVN and CAl and CA2 subregions of the hippocampus (69) .
The suppressive effects of each of the agents examined in this study, especially DEX, were apparently more pronounced on neurotransmitter-stimulated than on unstimulated iCRH secretion. Although it is not known whether this different sensitivity to inhibitory influences of the hypothalamic CRH neuron is present in vivo, it might be tempting to speculate that in states where the CRH neurons are activated, the brain eventually tries to shut off CRH secretion by rendering the CRH neuron more sensitive to a given level of glucocorticoid. It should be pointed out, however, that basal CRH secretion in vitro and in vivo may represent different types of secretion.
Whereas the latter may be a result of stimulatory and inhibitory inputs brought to the PVN from higher central nervous system centers, the former may represent autonomous hypothalamic CRH secretion. In our in vitro system, an alternative and/or additional explanation is a possible nonspecific release of CRH from injured cells.
Our data may help explain some related clinical observations. It has long been known that injection of morphine to patients undergoing heart surgery suppresses the activity ofthe HPA axis (70 (71) , it seems that their effects on CRH secretion is 4 receptor-mediated. This is supported by our findings that the specific 6 agonist met-enkephalin (71) fails to inhibit 5HT-stimulated iCRH secretion (Calogero et al., unpublished information). Additional mechanisms for morphine-induced HPA axis suppression should be considered. Rittmaster et al. have shown that morphine blunts ACTH response to exogenous CRH in humans (72). This blunting could be due to suppression of endogenous CRH or vasopressin by morphine and/or to stimulation of hypothalamic factor(s) that inhibit ACTH secretion. Note that the presence of hypothalamic corticotropin-inhibiting factor(s) has been previously suggested (73) . Efforts by Rittmaster et al. to show direct inhibition ofrat dispersed anterior pituicytes by morphine failed to show any effect (72).
Patients with Cushing's disease develop secondary (central) adrenal insufficiency after successful transsphenoidal excision of their ACTH-secreting pituitary adenoma (74) . This observation is compatible with our findings that neurotransmitter stimulation of hypothalamic CRH secretion is strongly inhibited by both ACTH and glucocorticoids. That the adrenal insufficiency observed in these patients is hypothalamic rather than pituitary is strengthened by the finding that most of these patients demonstrate a plasma ACTH response to exogenous ovine CRH (75) .
A definitive role for CRH in any major disease process has not yet been elucidated. We have recently advanced several lines of data to suggest that hypercortisolism in major depression represents a defect at or above the hypothalamus, resulting in the hypersecretion of CRH. We have hypothesized that such a defect could reflect inadequate restraint of the CRH neuron by cortisol exerting its long-loop negative feedback (76). This study, showing the ultrashort negative feedback loop by CRH upon itself, as well as short negative feedback loop on CRH neurons by POMC-related peptides, further extends the list of possible feedback abnormalities that could be involved in hyperactivity of the hypothalamic CRH system.
In conclusion, our data suggest the presence of multiple negative feedback control loops involved in the regulation of hypothalamic CRH secretion. These include an ultrashort CRH-mediated loop, a short hypothalamic POMC-derived peptide loop, and a long, glucocorticoid-mediated negative feedback loop. All of these regulatory circuits could be clearly shown to inhibit neurotransmitter-stimulated CRH secretion by isolated rat hypothalami.
